ASC30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Ascletis Pharma (China) Co · Phase 1/2 · Completed · Enrollment 115
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| SAD Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 5 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 6 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 7 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 8 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |